Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report

Table 2 Retrospective analyses of intracranial SFT treated with monotherapy

Ref.	Yr	Number of participants	CNS	Drug	RECIST		Choi		Median PFS in mo
					PR	SD	PR	SD	RECIST	Choi
Park et al[22]	2011	14	6	Temozolomide + bevacizumab	2	12	11	2	10.8	9.67
Stacchiotti et al[23]	2012	35	6	Sunitinib	2	17	14	5	6	7
Valentin et al[24]	2013	5	1	Sorafenib	NA	2	NA	NA	NA	NA
Maruzzo et al[25]	2015	13	NA	Pazopanib	1	8	5	4	4.7	NA
Ebata et al[26]	2018	9	2	Pazopanib	0	8	4	2	6.2	NA
Martin-Broto et al[27]	2019	36	5	Pazopanib	2	21	18	9	5.57	5.57

RECIST: Response Evaluation Criteria in Solid Tumors; Choi: Choi response criteria; PR: Partial response; SD: Stable disease; PFS: Progression-free survival; NA: Not available.